The following statement is attributable to:
Jesse M. Ehrenfeld, M.D., M.P.H.
President, American Medical Association
“The American Medical Association (AMA) applauds the Drug Enforcement Administration’s (DEA) decision to extend flexibilities in the prescribing of controlled substances based on telehealth patient visits through December 31, 2024. The AMA is grateful the DEA recognizes patients being treated with these medications, including medication to treat opioid use disorder, often have challenges securing and traveling to in-person appointments, and that the agency is committed to avoiding lapses in their care. The AMA will continue to encourage DEA, as it revises the rules, to provide an appropriate balance between advancing patients’ access to care via the mix of in-person and virtual services that best meets their needs while also ensuring patient safety.
Media Contact
About the American Medical Association
The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care. The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.
